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Extracellular RNAs (exRNAs) have been identified in all tested biofluids and have been associated with a
variety of extracellular vesicles, ribonucleoprotein complexes and lipoprotein complexes. Much of the interest
in exRNAs lies in the fact that they may serve as signalling molecules between cells, their potential to serve as

Journal of Extracellular Vesicles 2015.# 2015 Louise C. Laurent et al. This is an Open Access article distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commercial use, distribution, and
reproduction in any medium, provided the original work is properly cited.
1
Citation: Journal of Extracellular Vesicles 2015, 4: 26533 - http://dx.doi.org/10.3402/jev.v4.26533
(page number not for citation purpose)
biomarkers for prediction and diagnosis of disease and the possibility that exRNAs or the extracellular
particles that carry them might be used for therapeutic purposes. Among the most significant bottlenecks to
progress in this field is the lack of robust and standardized methods for collection and processing of biofluids,
separation of different types of exRNA-containing particles and isolation and analysis of exRNAs. The
Sample and Assay Standards Working Group of the Extracellular RNA Communication Consortium is a
group of laboratories funded by the U.S. National Institutes of Health to develop such methods. In our first
joint endeavour, we held a series of conference calls and in-person meetings to survey the methods used among
our members, placed them in the context of the current literature and used our findings to identify areas in
which the identification of robust methodologies would promote rapid advancements in the exRNA field.
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I
nvestigators in the Extracellular RNA Communication
Consortium are probing avariety of scientific questions,
such as elucidating mechanisms responsible for the
biogenesis of RNA-containing extracellular particles, their
uptake and potential function in recipient cells; discovering
extracellular RNA (exRNA) biomarkers for various diseases
and developing exRNA-based therapeutics. Although a
majority of the projects within the Extracellular RNA
Communication Consortium involve the characteriza-
tion of exRNAs, they have diverse goals and methods for
exRNA and extracellular particle isolation and analysis.
For example, many groups, particularly those focused
on biomarkers, require methods that give highly robust
results from samples obtained using a clinically feasible
collection and processing platform. The biomarker groups
may also prefer isolation methods that are more compre-
hensive rather than those that select for specific types of
particles and specific exRNAs, reasoning that these latter
manoeuvers might result in loss of potential biomarkers.
For other groups, such as those focused on understanding
the biogenesis of a specific type of particle, optimization of
yield and purity and bioactivity of that particle are the
driving forces. These varying priorities cannot always be
satisfied at the same time. For example, some protocols
optimized to give high yields of RNA may result in low
bioactivity or reduced RNA diversity. To discuss these
issues, this report will focus on the basic challenges as
identified by Extracellular RNA Communication Con-
sortium members. It will emphasize the need to develop
validated methods for sample collection, processing, RNA
isolation and next-generation sequencing (NGS) library
construction for exRNA analysis. We recognize that there
are a number of other pertinent topics that will not be
addressed here. Some of these have been addressed by
existing organizations, and others we intend to cover in
future reports. In terms of priorities that are being
addressed by other organizations, the International Society
on Thrombosis and Haemostasis has worked extensively
on standardization of detection of vesicles by flow
cytometry (1). The European Network on Microvesicles
and Exosomes in Health and Disease, supported by the
European Cooperation in Science and Technology frame-
work, has a working group focused on guidelines for
nomenclature and analysis. ISEV has published 2 position
papers on publication standards (2) and analysis of extra-
cellular vesicle (EV) RNA and bioinformatics (3). Finally,
the External RNA Controls Consortium has developed
spike-in control mixes for both long and small RNAs (4).
Context
The discovery of exRNAs in biofluids has sparked consi-
derable interest in their use as disease-specific diagnostic
and prognostic biomarkers. However, the discovery of
specific exRNAs as ‘‘disease-specific’’ reporters depends
on the notion that differential profiles of exRNAs across
different samples is predominantly reflective of changes
related to the disease process, rather than differences ari-
sing from the use of different exRNA isolation or analysis
methods. Therefore, the discovery of robust disease-
specific exRNAs as clinically relevant biomarkers depends
on standardized techniques for sample processing and
exRNA measurement that minimize variability across tech-
nical replicates and across different measurement sites.
The development of standard techniques for exRNA
isolation and analysis has been challenging because of
the large number of interacting biological and experi-
mental variables. First and foremost, exRNAs are present
in variety of compartments that have diverse biophysical
properties. These compartments include EVs (5,6), lipo-
proteins (7) and ribonucleoprotein particles (8). Different
methods for isolating exRNAs could preferentially enrich
for exRNAs present in certain compartments, thereby
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2
(page number not for citation purpose)
Citation: Journal of Extracellular Vesicles 2015, 4: 26533 - http://dx.doi.org/10.3402/jev.v4.26533
introducing intentional or unintentional bias in the
discovery process. Second, exRNAs have been found in
every tested biofluid. Variables involved in biofluid sample
collection and processing include biofluid type, use
of preservatives, collection container material, holding
time and temperature and any centrifugation or filtration
methods used, each of which may influence the quantity,
quality and type of RNAs isolated. Third, bias introduced
during NGS library construction can be substantial
(914). Fourth, exRNAs are generally present at low
concentrations in biofluids, which makes it challenging to
obtain sufficient RNA for downstream assays, particularly
for NGS-based assays. Most recent studies suggest RNA
yields of 2050 ng/ml of total plasma (15) and 55 ng
of EV-associated RNA per ml of biofluid, both of which
are significantly less than the 1 mg of RNA typically used
in NGS analysis of RNA isolated from tissue. The low
amounts of input RNA required for NGS library con-
struction can lead to a higher incidence of adaptor dimer
by-products (15), as well as potential sampling errors,
resulting in high variability in the measurement of low
abundance RNAs. Finally, inhibitors present in biofluids
or in collection methods may confound molecular assays,
including both qRT-PCR and NGS-based methods.
In the following sections, we will give a brief overview of
the relevant literature, followed by a description of prelimi-
nary data shared by members of the Extracellular RNA
Communication Consortium. We will conclude with poten-
tial future directions. In future collaborative studies, we aim
to develop a clearer understanding of common sources
of biological and experimental variability. We also strive to
identify robust and standardized methods for sample collec-
tion and processing, RNA isolation and exRNA analysis.
Such techniques will promote the success of efforts to dis-
cover exRNA biomarkers, to understand exRNA biology
and to develop therapeutic approaches using exRNAs.
Methodology for sample collection and
isolation of EVs and exRNAs
As part of an effort to address key topics in the field,
the Extracellular RNA Communication Consortium has
set up several working groups directed at the challenges
associated with the isolation and analysis of exRNAs. Of
these, the Sample and Assay Standards Working Group
(SAS WG) was tasked with assessing the current state
of the art for methods for biofluid sample collection,
exRNA isolation and exRNA analysis. To this end, the
SAS WG surveyed the protocols currently employed by
the 19 laboratories in the Extracellular RNA Commu-
nication Consortium.
Biofluid collection and processing methods
Witwer et al. (16) comprehensively reviewed the numerous
published reports demonstrating that EVs and exRNAs
can be found in a wide variety of biofluids and showing
that sample collection and processing methods can affect
results of downstream assays. One of the most significant
variables for sample collection is the choice of antic-
oagulant used for plasma samples, as it has been noted
that they can influence both the number of EVs in plasma
and the performance of downstream assays.
The International Society on Thrombosis and Haemos-
tasis has been active in developing standardized methods
for measurement of microparticle counts, particularly in
plasma (17). A recent study used these methods, recognizing
that the formation of EVs in vitro after sample col-
lection could confound accurate measurement of extra-
cellular biomarkers, to compare the levels of EVs in plasma
collected in acid-citrate-dextrose (ACD, Becton-Dickinson,
Franklin Lakes, NJ, USA), heparin (Becton-Dickinson),
citrate (Becton-Dickinson), citrate-theophylline-adenosine-
dipyridamole (Becton-Dickinson) and citrate phos-
phate dextrose adenine (Greiner Bio-One International,
Kremsmunster, Austria) tubes (18). EVs were measured
by flow cytometry and the ZYMUPHEN assay (Aniara,
Westchester, Ohio, USA). This study found that the pre-
sence of citrate was correlated with a lower EV count,
postulating that this might be due to chelation of calcium
by citrate. The study also found that the dextrose in ACD
tubes appears to inhibit in vitro vesiculation, compared
to tubes containing citrate only. In a separate study, the
Breakefield group has observed that heparin binds to EVs
and blocks their transfer between cells (19).
Outside the exRNA literature, it has been appreciated
that the most commonly used anticoagulants, heparin
and citrate, interfere with PCR (20,21). The Witwer et al.
review discusses this point, mentioning the use of the
alternative anticoagulants EDTA and NaF/KOx. The
authors recommend collecting samples in multiple tube
types, because different downstream assays will likely
show different sensitivities to specific additives (16).
The most common biofluids studied by members of
the Extracellular RNA Communication Consortium were
serum and plasma, but there were groups that evaluated
cerebral spinal fluid (CSF), cell culture supernatant, saliva
and bile. Six of the groups studying serum or plasma, as
well as the groups studying CSF, used biofluid samples
collected using methods that did not include a robust cell
removal step (such as high-speed centrifugation or mem-
brane filtration) prior to freezing for long-term storage.
Two groups studying serum and plasma performed a cell
removal step prior to freezing, either by centrifugation at
14,000g or filtration through a 0.8 micron membrane
filter. All groups completed initial sample processing
within 2 hours of collection with long-term storage of
samples in 12 mL aliquots at 808C.
The Skog group has tested the yields of several micro-
RNAs (miRNAs) and long RNAs as measured by qPCR.
They noted that, for plasma collection, heparin strongly
interfered with downstream qPCR. Likewise, specimens
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collected in citrate (Becton-Dickinson, NJ, USA) or
plasma preparation tubes (PPT, containing both dipotas-
sium EDTA as the anticoagulant and a gel polymer that
forms a barrier between the plasma and cellular material
after centrifugation, Becton-Dickinson, NJ, USA) showed
overall higher CT values corresponding to lower RNA
concentrations as compared to specimens collected in plain
EDTA tubes. None of the Consortium groups reported
using NaF/KOx as an anticoagulant, as it is not a com-
monly used additive for clinical lab draws. Although the
effects of the different anticoagulants on downstream
assays are important considerations when choosing a
sample collection tube type, it can be difficult to predict the
future uses of banked samples, and it is often not feasible
to collect in multiple tube types from the same patient. Many
Consortium groups are using EDTA as the anticoagulant
for plasma sample collection for projects in which qPCR
and/or NGS are anticipated to be the downstream read-
outs. We appreciate that a comparison of in vitro vesicula-
tion in ACD versus EDTA has yet to be performed.
The major rationale for methods that include a robust
cell removal step is that they increase the likelihood that
the extracted RNAs will represent exRNAs as opposed to
intracellular RNAs (i.e. RNAs that are from cells that are
intact in the source biofluid, but are lysed during sample
processing or storage). However, these methods require
processing of fresh samples using specialized protocols,
and therefore they cannot be applied to previously banked
biofluid samples. Moreover, concerns have been raised in
discussions among Extracellular RNA Communication
Consortium members regarding potential loss of larger
EVs with membrane filtration or centrifugation speeds
greater than 2,000g. At this time, there is no clear
consensus on this point, other than the need to record in
detail the sample collection methodology used.
Experience from the Wong group, which studies sali-
vary exRNAs, reveals the need for customized processing
methods for specific biofluids. In these experiments, RNA
extracted from saliva that had been centrifuged at
2,600g contained significant levels of rRNA. Because
intact rRNAs have been shown to be largely absent from
RNA extracted from EVs (6,22), the investigators were
concerned that there might be excessive cell lysis. However,
subsequent centrifugation at 10,000g for 5 minutes
showed that all of the intact rRNAs detectable by
Bioanalyzer (Agilent, Santa Clara, CA, USA) were found
in the pellet; this observation, combined with the migration
of the rRNA peaks (which was more rapid than typically
seen for eukaryotic 28S and 18S rRNAs) supported the
notion that these rRNAs were of bacterial origin. This
conclusion was further confirmed by NGS analysis of
these samples, in which only 614% of reads mapped to the
human genome and 6070% of reads mapped to the
microbiome, with the majority of sequences representing
bacterial rRNAs. These findings demonstrate that rRNA
contamination in salivary exRNA samples, which would
be presumed to be of intracellular origin in most biofluids,
was likely due to the high bacterial load in saliva.
Special considerations when using cell culture
supernatants
EVs can be isolated from cell culture supernatants, and
the ability to experimentally manipulate the cells and
produce large volumes of supernatant make these attrac-
tive systems to use for study of the biogenesis and func-
tions of EVs. However, there are specific variables that
must be taken into account in these studies. For example, if
the cell culture medium is supplemented with foetal bovine
serum, the serum should be depleted of endogenous EVs.
This task is typically done by ultracentrifugation for
prolonged periods of time or by immunoaffinity methods
using antibodies raised to antigens commonly found on
the surfaces of bovine EVs. Because these methods do not
fully deplete the serum of EVs and exRNAs (23), it is
preferable to use serum-free media formulations when
possible. Both the Breakefield and Patel groups have
observed that cell density can affect the release of EVs
into the cell culture supernatant, with increasing density
associated with decreased release. A possible explanation
for this phenomenon is that EVs can be transferred from
cell to cell, and a higher density of cells favours cell-to-cell
trafficking over release into the supernatant.
EV and particle enrichment methods
We note that a discussion of nomenclature for EVs and
other extracellular particles remains an area of active
debate that is outside the scope of this report. Although
defining subtypes of EVs based on the mechanism of
biogenesis is an attractive method, such a scheme cannot
be easily applied given the dearth of knowledge about these
processes (24). One convention that has been adopted is to
name the vesicles based on the source of the biofluid.
Terms such as epididimosomes, argosomes, prominino-
somes, prostasomes, dexosomes, texosomes, archaeosomes
and oncosomes have all been used in this regard (25).
Another classification scheme involves definition by size of
the EV. This classification scheme is built on the observa-
tion that EVs derived from distinct biogenic mechanism
often differ by size (26,27). The term ‘‘exosomes’’ has been
used to refer to EVs40100 nm in size, whereas the term
‘‘microvesicles’’ is typically used to refer to larger EVs of
1001,000 nm (26). We recognize that these size cut-offs
are somewhat arbitrary (24) and that EVs defined solely by
size-based nomenclatures are likely to be heterogeneous in
molecular composition (28). Moreover, EVs isolated using
one method are likely to differ from those isolated using
another (29). The available data is rather preliminary for
establishing prescriptive standards for EV definition or
isolation (24,25,29). As a result, it is important for in-
vestigators to specify the operational definition of the EVs
under investigation and the methods used for EV isolation
Louise C. Laurent et al.
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and assessment of EV purity and size, to enable meaningful
comparison of results among different studies.
Two recent studies have compared the performance of
different EV isolation methods. Kalra et al. compared
differential ultracentrifugation, EpCAM affinity purifica-
tion and OptiPrep (Sigma-Aldrich, St.Louis, MO, USA)
density gradient ultracentrifugation on plasma samples.
They used mass spectrometry, detection of the exosome
marker TSG101 and electron microscopy to evaluate the
yield and purity of their preparations (30). The report
concluded that density gradient ultracentrifugation gave
the best results, but that quicker and less laborious
methods would be valuable for biomarker studies.
Van Deun et al. applied 4 EV isolation protocols to
conditioned medium: differential ultracentrifugation, Op-
tiPrep (Sigma-Aldrich) density gradient ultracentrifuga-
tion, ExoQuick (System Biosciences, Mountain View, CA,
USA) precipitation, and Total Exosome Isolation (Life
Technologies, Carlsbad, CA, USA) precipitation. They
evaluated the purity and RNA content of the resulting EVs
by assessing particle count and morphology by nano-
particle tracking analysis and electron microscopy, enrich-
ment of CD63 and other exosomal marker proteins,
presence of contaminating AGO2 and gene expression
microarray (Agilent) (31). The report concluded that, al-
though density gradient ultracentrifugation was the most
time- and labour-intensive method, it produced the highest
yield and purity EVs, as well as the highest complexity
RNA content.
Extracellular RNA Communication Consortium groups
have used a variety of methods to enrich for EVs. These
methods can be divided into 5 classes: precipitation,
filtration, gel filtration, affinity purification and differen-
tial ultracentrifugation.
Precipitation-based methods
Three groups reported using a kit-based precipitation
technique [e.g. ExoQuick (System Biosciences) and the
Total Exosome Isolation Reagent (Life Technologies)].
These techniques precipitate EVs of various sizes, as well
as ribonucleoprotein complexes, from biofluids. The kits
use polyethylene glycol (PEG)/sodium chloride (NaCl)-
based methods initially developed for precipitation of
macromolecular complexes, including virus particles. It
is believed that the PEG polymers sterically exclude the
macromolecular complexes from a portion of the solvent
volume, increasing the effective concentration of the par-
ticles to their solubility limit (32). It has been noted by
Extracellular RNA Communication Consortium mem-
bers that EVs isolated using these methods display dif-
ferent light-scattering properties and particle sizes (as
measured using the NanoSight instrument (Malvern
Instruments, Malvern, UK)) and lower bioactivity
compared to those isolated by ultracentrifugation (see
below, ‘‘Differential centrifugation-based methods’’).
These methods also sediment ribonucleoprotein and
lipoprotein complexes (33), which have themselves been
reported to carry small RNAs, including miRNAs (7).
Consequently, unintended co-purification of vesicular
and non-vesicular macromolecular structures could po-
tentially complicate subsequent analyses.
Membrane filtration-based methods
Two Consortium groups reported using sequential frac-
tionation of cell culture supernatant through syringe filters
with successively smaller pore sizes. According to these
groups, this approach had a number of potential advan-
tages over other methods for EV purification: (a) improved
homogeneity in the size of vesicles obtained; (b) avoidance
of high g-forces involved in ultracentrifugation-based
approaches (34,35); (c) higher yield of EVs and exRNAs;
(d) avoidance of precipitants that might interfere with
downstream applications, in contrast to PEG/NaCl pre-
cipitation; (e) no need for specialized large equipment,
compared to ultracentrifugation.
However, the method used by the 2 Consortium groups
was quite time-consuming, as filtration through mem-
branes with small pore sizes (20 nm) was slow and the
filters sometimes clogged. In addition, there are 2 signi-
ficant concerns regarding the filtration approach, which
need to be further studied: the potential disruption of
EVs due to shear forces as they pass through the filters
and the co-purification of non-vesicular particles and
protein aggregates. It is possible that these effects can be
mitigated (e.g. by adjusting the chemical composition,
pore size, uniformity of pore size and structure of the
filters or by controlling the pressure applied during
filtration), but such studies have not yet been performed.
Gel filtration-based methods
The basis of gel filtration chromatography is that mole-
cules pass through a bed of porous beads, with the speed
of passage determined by molecular size and shape, as
well as interactions between the beads, buffers and mole-
cules. Overall, large molecules do not enter the pores
and therefore move through the column quickly; small
molecules readily enter the pores and pass through the
column more slowly. Beads of different chemical compo-
sitions that affect their hydrophobicity/hydrophilicity,
compatibility with different buffers and resistance to
different solvents are available in a variety of pore sizes.
Gel filtration has been used extensively to purify nucleic
acids, peptides, proteins, lipids and viruses. Methods using
Sepharose 2B beads (Sigma-Aldrich, St. Louise, MO,
USA) to purify EVs for RNA and proteomic profiling
(36) and for separating platelet-derived vesicles greater
than 70 nm in diameter from HDL and protein (37) have
been reported. None of the Extracellular RNA Commu-
nication Consortium groups used gel filtration chromato-
graphy (also referred to as ‘‘size exclusion chromatography’’)
as their primary modality for EV or non-vesicular particle
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isolation. However, it has been reported in the literature
that gel filtration results in EV co-isolation with high-
density lipoprotein (HDL) and low-density lipoprotein
(LDL) particles (38). The overall consensus in the Extra-
cellular RNA Communication Consortium at this point is
that further studies are required to fully characterize the
effects of different variables (particularly bead type and
buffer composition) on fractionation of different EV and
non-vesicular particle types.
Affinity purification-based methods
None of the Extracellular RNA Communication Con-
sortium groups reported using affinity-based methods for
purification of EVs routinely, although some groups had
experience with this approach (39). The groups focusing
on purification of exRNA-containing lipoprotein com-
plexes used it on a regular basis (see below, ‘‘Isolation of
exRNA-containing lipoproteins’’). In this method, bio-
fluids are passed over solid phase substrates coupled to
antibodies or other molecules that bind to specific anti-
gens on the surfaces of the extracellular particles. This
strategy has been used to isolate extracellular particles
that express disease-specific antigens. For example, puri-
fication of epithelial tumour-derived EVs from plasma
can be achieved by selection for EVs carrying tumour-
specific (e.g. PSMA) or epithelial (e.g. EpCAM) markers
using magnetic bead sorting (40,41). However, the speci-
ficity and yield from this approach is highly dependent
on the differential expression of specific markers on
subpopulations of EVs, the type and performance of the
antibodies used and the type and surface size of the
magnetic beads used. Also, non-vesicular RNAs may be
physically entrapped by this purification method. Thus,
optimization of this method is critically needed to assess
whether enrichment of disease-specific circulating EVs
will be useful for exRNA biomarker discovery. Micro-
fluidics devices have also been used to capture EVs by
antibody affinity (39). A combination of different anti-
bodies has been shown effective in enriching for normal
EVs, and a specific cocktail of antibodies could be used
to enrich for EVs from a specific disease, e.g. cancer.
Differential centrifugation-based methods
Sixteen of the Extracellular RNA Communication Con-
sortium groups reported using a version of the classic
differential centrifugation approach to collect EVs (4244).
Typically, there is a low-speed centrifugation step (300
3,000g for 530 minutes) to remove cells and cell debris,
a high-speed centrifugation step (10,00020,000g for
30 minutes) to remove larger classes of EVs and then an
ultracentrifugation step (100,000167,000g for 118
hours) to collect the exosome pellet for analysis. Sedi-
mentation efficiencies vary with rotor type (k factor) and
fluid viscosity, accounting for the range in speeds and
durations of ultracentrifugation (4547).
The differential centrifugation approach is suppor-
ted by more than a decade of research in the exosome/
microvesicle field, which was preceded by more than
50 years of research in the field of virology. This metho-
dology has been demonstrated in many publications to
enrich for many of the major sources of exRNAs, includ-
ing different types of EVs, as well as endogenous viruses
and some protein aggregates. However, differential cen-
trifugation has several drawbacks. In practical terms, it
requires extensive processing of samples and is difficult to
scale up, particularly in terms of numbers of samples. The
populations of vesicles/particles pelleted by the high-speed
centrifugation (10,00020,000g) and ultracentrifuga-
tion steps (100,000g) are heterogeneous in size (35),
although this can be reduced with a pre-filtration step to
remove the largest vesicles (42). It has not been established
how efficiently non-vesicular exRNAs (such as exRNAs
associated with ribonucleoprotein or lipoprotein com-
plexes) are pelleted by the ultracentrifugation step. In
addition, it has been noted by some members of the
Extracellular RNA Communication Consortium that
prolonged ultracentrifugation appears to alter the mor-
phology of EVs. Given that the yield of exRNA using
differential centrifugation is markedly lower than when
using the other methods discussed above and that dif-
ferential centrifugation requires specialized large equip-
ment, many groups will prefer to use a more facile method,
unless differential centrifugation offers a substantial benefit
for their particular experimental system. Finally, the
differential centrifugation approach can be difficult to
standardize. One reason for this is the variation in ultra-
centrifugation speed and duration seen in commonly used
protocols. Moreover, even when the g-force and dura-
tion parameters are held constant, results can differ with
sample volume and viscosity, rotor type (e.g. fixed angle vs.
swing-out), the dimensions and chemical composition of
centrifuge tubes and instrument model (45).
It has been found that density gradient ultracentrifu-
gation (DGUC) performed after standard ultracentrifu-
gation (48,49) or after an alternative EV concentration
method (31) can result in higher purity and better
uniformity of size of EVs. However, the only groups in
the Consortium who reported using it regularly were the
groups focusing on lipoproteins (see below, ‘‘Isolation of
exRNA-containing lipoproteins’’).
Isolation of exRNA-containing lipoproteins
In addition to EVs, exRNA is also transported by lipo-
proteins in plasma (7). The most abundant lipoproteins
are very low-density lipoproteins (VLDL), LDL, and HDL.
As their names suggest, lipoproteins are classified based
on their density  VLDL (0.941.006 g/mL), LDL
(1.0061.063 g/mL) and HDL (1.0631.21 g/mL). Apo-
lipoprotein B (apoB) containing VLDL (approximately
60 nm in diameter) is synthesized and secreted by the liver.
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It undergoes remodelling in circulation due to lipase
hydrolysis of VLDL triglycerides. This process produces
smaller but denser LDL (25 nm in diameter). Conversely,
apolipoprotein A-I (apoA-I), the structure-function pro-
tein in HDL (712 nm in diameter), is secreted by the
liver and small intestines in a nascent lipid-poor form
that is quickly lipidated with cholesterol and phospho-
lipids by ATP-binding cassette transporter A1 (50). As
such, VLDL and LDL are identified as apoB particles
and HDL is defined by apoA-I, and thus affinity chro-
matography can be used to isolate distinct lipoprotein
classes. Both apoB and apoA-I particles transport and
deliver miRNAs to recipient cells (7).
Historically, the most common method for isolation
of lipoproteins was density gradient ultracentrifugation
(DGUC), using solutions of salts, such as potassium
bromide, to set up the gradient. By using distinct density
layers, each lipoprotein class can be separated by ultra-
centrifugation. This process requires multiple 24 h runs to
sequentially isolate VLDL, LDL and finally HDL; it then
requires extensive dialysis to remove the salts from the
density buffers. The main benefit of DGUC is the high
yield of lipoproteins that can be obtained (e.g. 1 mg
of total HDL protein per 1 mL of plasma). The dis-
advantages of DGUC are that it involves exposures to
high gravitational forces and high salt buffers; it is time-
consuming, and exosomes (1.101.21 g/mL) have a similar
density to HDL and can be co-purified with HDL from
plasma samples (51).
Fast protein liquid chromatography (FPLC) with a
size-exclusion gel filtration column can cleanly separate
HDL from exosomes due to the relatively large difference
in size (approximately 10 nm in diameter for HDL and
40100 nm for exosomes). Given the limited input volume
(1 mL), FPLC is often used downstream of DGUC.
A disadvantage of FPLC is that other macro-protein com-
plexes of similar size can co-fractionate with lipoproteins
(e.g. antibodies). At this time, these potentially contaminat-
ing co-fractionated complexes or proteins have not been
found to carry miRNAs or other RNA species, and so
this may not be as important an issue for exRNA studies.
Another method for isolation of lipoproteins is im-
munoaffinity purification using antibodies raised against
apoB or apoA-I. Micro-spin columns can be loaded with
Sepharose 4B beads conjugated to anti-apoB or anti-
apoA-I antibodies (Academy Bio-medical Co., Houston,
TX, USA) to purify VLDLLDL or HDL, respectively.
This method only requires a few hours, but is limited by
the binding capacity of the columns, which results in low
yields of total lipoprotein (100 mg of total HDL protein
per mL plasma). Compared to DGUC and FPLC, im-
munoaffinity purification is the least specific method, due
to non-specific interactions. The main advantage of this
method is that it can rapidly isolate lipoproteins from
small sample volumes.
The best electron-microscopy-based approach for iso-
lation of highly pure HDL from plasma is to perform
DGUC followed by FPLC and to collect HDL fractions
based on the distribution of total cholesterol. Because
LDL and VLDL are similar in size to exosomes, FPLC
alone results in cross-contamination of these particles;
therefore, DGUC followed by FPLC is also a sound stra-
tegy for separation of apoB-containing particles from
exosomes. It is important to appreciate that the ultracen-
trifugation step of the differential centrifugation strategy
for isolation of EVs (see below, ‘‘Differential centrifugation-
based methods’’) will also co-pellet both LDL and HDL.
In summary, DGUC, FPLC and immunoaffinity methods
can all be used to isolate miRNA carrying VLDL,
LDL and HDL. Each method has its own benefits and
limitations, and the use of multiple methods in tandem
is a useful strategy for improving the purity of the final
material.
Summary of EV and particle enrichment methods
Based on the discussions held in the SAS WG, it is clear
that a wide range of methods are used by members of the
Extracellular RNA Communication Consortium. It is
also apparent that there is a lack of consensus regarding
either the preferred methodology or accepted experi-
mental parameters for the enrichment of EVs or other
exRNA-containing particles from biofluids. Systematic
studies comparing the exRNA content and bioactivity
of EVs isolated using different approaches are starting
to be reported. Such studies are essential for promoting
progress in this field. To further address these issues,
2 subgroups have been formed under the umbrella of
the SAS WG: the Vesicle Isolation and Function Sub-
group and the Non-Vesicular or Lipoprotein-Associated
Subgroup.
RNA isolation methods
Efforts to determine optimal methods for isolation and
analysis of exRNA from biofluids have been initiated by
several investigators over the past 3 years (5260). Eldh
et al. (52) compared RNA yield (by spectrophotometry
and qPCR), purity (by spectrophotometry) and size dis-
tribution (by Bioanalyzer (Agilent)) of exRNAs isola-
ted from cultured cell media using several different kits
and methods, noting the best results with the Exiqon
miRCURY kit (Vedbaek, Denmark) and adequate re-
sults with the miRNeasy (Qiagen, Venlo, Limburg) and
mirVana (Life Technologies, Carlsbad, CA, USA) kits for
small RNAs.
McAlexander et al. (53) also tested different commer-
cially available RNA isolation kits to determine the opti-
mal method for improving yield of extracellular miRNAs
(assayed by qRT-PCR for synthetic miRNA spike-ins
as well as endogenous miRNAs). The Exiqon miRCURY
biofluids kit was determined to have the best performance
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among the tested methods for isolation of miRNA from
platelet-poor plasma and CSF in this study.
Sedlackova et al. compared the miRCURY RNA iso-
lation kit (Exiqon) and the Circulating Nucleic Acid kit
(Qiagen, Valencia, CA, USA) on plasma samples from
pregnant women and concluded that the miRCURY kit
was superior for isolation of both miRNAs and DNA
based on qPCR of miR-15 and miR-451 for miRNAs,
and AR and DYS14 for DNA (54).
Kroh et al. compared the miRNeasy (Qiagen) and the
mirVana PARIS (Life Technologies) kits on serum and
plasma and found that the miRNeasy (Qiagen) kit using a
10 volume of the TRIzol reagent (Life Technologies)
had a yield 23 that of the mirVana (Life Technologies)
kit (55).
Monleau et al. used serum and compared the miRNeasy
mini (Qiagen), plasma/serum circulating RNA purifica-
tion (Norgen Biotek, Ontario, Canada) and Nucleospin
miRNA plasma (Macherey-Nagel, Duren, Germany) kits,
using the TaqMan low-density array for miRNA (Life
Technologies) as a readout. They concluded that the
Nucleospin kit resulted in a higher number of detected
miRNAs (56).
Moret et al. isolated miRNAs from serum using the
mirVana PARIS (Life Technologies), TRIzol LS (Life
Technologies) and miRNeasy serum/plasma (Qiagen) kits
using different amounts of spike-in control RNA and using
NanoDrop, Bioanalyzer (Agilent) and the Affymetrix
miRNA 3.0 microarray (Affymetrix, Santa Clara, CA,
USA) as the readout. The results focused on a comparison
of the quantification, size distribution and microarray
results for the miRNeasy (Qiagen) method with different
amounts of spike-in RNA. Moret et al. concluded that
using a 10-fold lower amount of spike-in than that
recommended by the manufacturer gave the best yield
and sensitivity on the microarray. An in-depth comparison
of results for the 3 purification methods was not shown,
but the authors stated that methods that require organic
extraction, such as TRIzol LS (Life Technologies), should
be avoided (57).
The types of RNA isolation methods used by labora-
tories in the Extracellular RNA Communication Consor-
tium varied widely. The large majority of methods used
solutions containing guanidinium isothiocyanate (GITC)
for disruption of EVs and other exRNA-containing parti-
cles. However, the methods differed at 2 subsequent steps:
(a) whether they include a phenol/chloroform extraction
[e.g. TRIzol (Life Technologies), miRNeasy (Qiagen) and
mirVana (Life Technologies)] or not [e.g. miRCURY
Biofluids (Exiqon), Plasma/Serum Circulating and Exo-
somal RNA Purification (Norgen Biotek) and Direct-Zol
(Zymo, Irvine, CA, USA)]; and (b) whether the exRNA is
concentrated using alcohol precipitation (e.g. the standard
TRIzol protocol) or a spin column (nearly all of the other
methods).
Comparisons between different exRNA isolation kits
Several groups in the Extracellular RNA Communication
Consortium have performed pilot studies comparing
26 RNA isolation kits. Here, we will discuss preliminary
results from 3 of these groups for illustrative purposes
only, to show the challenges encountered when attempt-
ing to draw general conclusions from studies performed
in different laboratories. We wish to emphasize that a
large multicentre comparison has not been done; we do
not intend for readers to base decisions on the choice of
RNA isolation method for their studies on the results
presented here alone.
Three groups each compared RNA isolation from
plasma and/or serum using 3 different commercial kits.
There was little overlap in the kits used by the groups.
The Gandhi group isolated RNA from frozen serum and
plasma using 3 kits: the miRNeasy Mini Kit (Qiagen) with
0.2 ml input volume, the Circulating RNA Isolation Kit
(Norgen Biotek) with 1 ml input volume and the Exosome
RNA Isolation Kit (Norgen Biotek) with 1 ml input
volume. The RNA samples were eluted in 50 or 100 ml
and quantified using the NanoDrop (Nanodrop). They
were further analysed using the nCounter miRNA Ex-
pression assay (nanoString, Seattle, WA, USA), which
interrogates 800 miRNAs. After obtaining the results, it
was learned from the manufacturer that the 2 Norgen kits
are the same kit marketed under 2 different names;
therefore, the samples isolated using these 2 kits can be
considered as replicates. As expected, the yield and
performance of the RNA samples isolated using these 2
kits were very similar. Although the yield of RNA was
lower for the Norgen kits than for the miRNeasy kit,
the number of detectable miRNAs as assessed by the
NanoString assay was higher for the Norgen kits. It also
appeared that the RNA yield for plasma and serum
samples was similar, but the number of detectable miRNAs
was higher for the plasma samples than the serum samples.
Overall, the overlaps in the sets of genes detected in the
different samples was quite good.
The Freedman group isolated RNA from 0.2 ml plasma
samples using 3 different commercial RNA isolation kits:
the miRCURY RNA Isolation Kit for biofluids from
Exiqon, the TaqMan miRNA ABC Purification Kit from
Life Technologies and the miRNeasy Serum/Plasma Kit
from Qiagen. All input plasma volumes and RNA elution
volumes were held constant across the 3 kits, and the
isolated RNA samples were analysed using 90 qRT-PCR
miRNA Assays (miScript miRNA Assays from Qiagen)
run on Dynamic Arrays on the BioMark System (Flui-
digm, South San Francisco, CA, USA). In this set of
experiments, the TaqMan ABC Kit showed the lowest
total exRNA yield, but it also showed the lowest CT and
standard deviation values (and therefore the highest
measured quantity) for detected miRNAs, indicating
that exRNA yield cannot be used as a definitive arbiter
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of the performance of an RNA isolation kit. The major
limitation of the Taqman ABC kit is that it is a targeted
kit, unlike the other kits used in this study, only isolating
selected or targeted miRNAs; thus it does not allow for
discovery of novel RNAs.
The Patel group isolated RNA from 0.5 ml fresh or
frozen serum and fresh or frozen plasma using 3 different
kits: the Plasma/Serum Circulating and Exosomal RNA
Purification Mini Kit (Norgen Biotek); the SeraMir
Exosome RNA Purification Kit (System Biosciences);
and the Total Exosome Isolation and Total Exosome
RNA Isolation Kit (Life Technologies). The RNA yield
was measured using NanoDrop (Nanodrop) and the
Bioanalyzer RNA Pico Kit (Agilent). With NanoDrop
(Nanodrop), the RNA yields were comparable for serum
and plasma samples and for fresh and frozen samples.
Each of these 3 groups used a different set of assays for
evaluating the yield of RNA (a panel of qRT-PCR assays;
NanoDrop and NanoString; NanoDrop and Bioanalyzer
(Agilent)). There was minimal overlap in the RNA isolation
kits used. For these reasons, it is not possible to draw strong
conclusions regarding the relative performance of the kits
across groups, even though they used the same biofluid types.
A fourth group, the Wong group, compared RNA yield
from 0.5 ml saliva samples using 6 RNA isolation methods:
(a) an organic extraction method (TRIzol LS); (b) 3 spin
filter-based methods [QIAamp Viral (Qiagen), NucleoSpin
(Clontech, Mountain View, CA, USA) and mirVana
(Life Technologies)]; and (c) 2 methods combining organic
extraction and spin filter clean-up [miRNeasy micro
(Qiagen) and Quick-RNA micro (Zymo)]. The purified
RNA samples were treated with DNase and then pre-
cipitated and resuspended in 10 ml RNase-free water. The
quantity and size distributions of the resulting RNA
samples were assessed using the RiboGreen reagent and
the Bioanalyzer (Agilent), respectively, with the best yields
from the NucleoSpin and miRNeasy micro kits. The
minimal overlap in the RNA isolation and analysis
methods used and the use of a different biofluid type by
this group prevents useful comparisons between this and
the other 3 studies.
Thus, despite the many studies that have been per-
formed thus far, we believe that a large-scale multicentre
effort, with NGS as the final readout, would be useful.
It will be challenging to reach a consensus method,
because all methods have their advantages and disadvan-
tages. It is important to appreciate that, when comparing
different methods, one needs to control for a wide number
of variables. For data to be comparable across labs and
methods, the different labs will need to work from a stan-
dardized sample set, as the efficiency and performance
of different methods will vary, depending on biological
differences between samples, such as the amount of
AGO2-bound miRNA or cell-free DNA (cfDNA), which
are isolated at different efficiencies by different methods.
For any experiment aimed at comparing 2 or more
methods of RNA isolation, it is important to report and
control for variables, some of which are listed below:
a. Sample collection and processing variables.
1) Sample type, including viscosity (e.g. serum,
plasma, platelet-poor plasma, urine, dilution in
PBS or other buffer, etc.).
2) Collection tube type and any additives.
3) Sample holding time and temperature for the
samples prior to processing.
4) Cell removal steps (centrifugation parameters;
type and pore size of filters used).
5) Frozen storage before or after processing.
b. Possibility that sample processing steps might remove
exRNA-containing EVs or protein or lipoprotein com-
plexes. For example, removing the platelets from plasma
is often done by centrifugation, but the protocols used
are not standardized, with some protocols including
fairly high g-force centrifugation steps that will also
pellet a fraction of the EVs. Thus, analysis of the
resulting supernatant can underestimate the exRNA
content.
c. Differential co-purification of cfDNA by different
methods and differential susceptibility of each RNA
quantification and analysis method to contaminating
DNA (see below, ‘‘Special considerations for exRNA
quantification’’).
d. Different methods will isolate exRNAs associated
with the various exRNA-containing vesicles/particles
(such as EVs and AGO2-containing ribonucleopro-
tein complexes) with different efficiencies. It is not
well understood for the large majority of protocols
what the co-purification rates are for these entities.
e. Variability in yield and complexity of exRNA popula-
tions due to differences in sample input. This type of
variability can be problem for input sample volumes at
both the high and the low end. For example, the yield
of exRNA can plateau with input sample volumes
greater than 1 ml, but low input volumes can result
in sampling error for low abundance RNAs. These
effects have not been systematically characterized.
f. The compatibility of the method with samples
collected in a clinically feasible workflow.
g. The ability to easily standardize and adopt the method
across multiple labs.
h. The efficiency of capture of RNAs of both high and
low molecular weight.
When evaluating the yield and performance of RNA,
it is helpful to use the method the operator is eventually
planning to use for the downstream analysis of the target
(i.e. if qRT-PCR is the analytical method that will be used,
a qRT-PCR based evaluation of RNA yield/reproducibil-
ity should be used rather than Bioanalyzer (Agilent), Qubit
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(Life Technologies), nanoparticle tracking analysis or
other method, because each method has a bias and may
not give the same result).
For interlab comparisons or validations of different
methods, we believe that it is important to include stan-
dardized samples, spike-ins and analysis reagents in the
study design. To address these and other related issues,
the SAS WG has formed the RNA Isolation Subgroup.
Special considerations for exRNA quantification
Quantification of exRNAs is particularly challenging,
given that they are typically present at low concentrations
and have a wide range of lengths (15 nt to thousands of
nucleotides), with a prominent population of small RNAs
(B200 nts). It is important to keep in mind that different
measurement techniques will yield very different total
amounts of RNA. Furthermore, it is important to con-
sider the characteristics of each quantification method,
in terms of the limit of detection, dynamic range and
specificity for nucleic acid type, so the most accurate
method can be used for the expected yield of RNA (61).
The lower limit for the NanoDrop is 2 ng/ml (with
increased variability in measurements at concentrations
below 5 ng/ml) and the upper limit is 3,000 ng/ml. In
many cases, it is probably not the best choice for exRNA
quantification due to the low yields of exRNA from most
biofluids; in addition, it is a spectrophotometric assay
and thus detects DNA and protein in addition to RNA.
The Qubit RNA Assay (Life Technologies, also avail-
able for microplate format assays as the Quant-iT RNA
Assay Kit and the Quant-iT RNA BR Assay Kit, Life
Technologies) is highly specific for RNA. However, the
lower limit at which it can confidently quantify RNA is
5 ng in a 200 ml assay volume; typically, purified exRNA
samples do not contain enough RNA to be quantified
using this method. The RiboGreen reagent (available as
the Quant-iT RiboGreen RNA Assay Kit and Reagent,
Life Technologies) has a lower limit of detection of 200 pg
in a 200 ml assay volume, but binds to DNA as effectively
as it binds to RNA. The use of the standards to generate
standard curves is essential for both the RiboGreen (Life
Technologies) and Qubit (Life Technologies) quantifica-
tion methods, as differences may appear between quanti-
fications done on different days. Assays adapted for a
multi-well plate format are very useful, utilizing a plate
reader to both increase the throughput of the assay and mini-
mize technical variability in the assay between samples.
Although all of these methods can be used to quantify
RNA, only the Bioanalyzer (Agilent), which has a lower
range limit of 50 pg/ml for the RNA Pico and Small
RNA Kits (Agilent), can evaluate the size distribution
of the RNA molecules. However, this method is not as
reproducible in terms of RNA quantification as the Qubit
(Life Technologies) or RiboGreen-based assays (Life
Technologies) and does not distinguish between RNA
and DNA. The Bioanalyzer (Agilent) methods are also
affected by impurities that can quench the fluorescent
signal. Variability in the height of the internal marker
peak, an uneven baseline and an imperfect size standard
ladder are indicators that there may be factors present
that compromise the accuracy of Bioanalyzer (Agilent)
quantification.
qRT-PCR is another valuable quantification method
that can be performed using a standard curve to allow for
absolute quantification of selected transcripts. Especially
while an RNA isolation protocol is being optimized,
qRT-PCR experiments should include a ‘‘no reverse tran-
scriptase’’ control to detect DNA contamination and a
spike-in positive control to evaluate for the present of
reverse transcriptase inhibitors.
An additional concern that may impact the choice of
measurement technique is potential contamination asso-
ciated with the different RNA isolation methods, which
can significantly influence RNA measurements due to the
low concentration of RNA molecules in many exRNA
samples. Guanidinium salts and organic solvents are used
in many RNA isolation methods, and carryover of these
will distort NanoDrop (Nanodrop) measurements. Gua-
nidinium salts and ethanol also interfere with the Ribo-
Green assay. GlycoBlue (Life Technologies), which is
frequently employed as a carrier for RNA precipitation,
is not compatible with the Qubit RNA assay (Life
Technologies).
Thus, the measured total RNA yield will vary based
on the quantification method used. We conclude that it
is necessary, for comparisons across experiments and
between groups, to select a consistent RNA quantifica-
tion method to ensure reproducible results. In choosing
a quantification method, it is important to consider the
sensitivity, nucleic acid specificity and reproducibility of
each method. For many groups, practical considerations,
such as availability of required equipment, cost and time
needed to run the assays, will also be factors in this choice.
Other variables in RNA isolation
Further complicating comparisons of different RNA iso-
lation methods is the fact that many of the kit-based
methods include optional Proteinase K (PK) and DNase
digestion steps. In addition, several groups have explored
using phosphorylation of exRNA samples to improve
small RNA sequencing library yield.
Proteinase K treatment. Within the Extracellular RNA
Communication Consortium, there has been significant
disagreement about the impact of PK digestion on yield
and quality of exRNA. PK may enable more effective
dissociation of exRNAs from protein complexes; at the
same time, it is possible that this dissociation of exRNAs
from protein complexes may make them more vulnerable
to RNases. To explore these possibilities, the Das lab
performed small RNA-seq on exRNAs purified from the
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same plasma sample without PK, with PK added prior to
GITC and with PK added in the GITC buffer. In this
experiment, addition of PK following addition of GITC
buffer to the sample resulted in an increase in RNA yield
compared to samples with no PK or PK added prior to
GITC and a modest increase in the number of miRNA
species detected. The increase in the number of miRNA
species detected was largely attributable to an increase in
detection of lower abundance miRNA species. Additional
experiments using multiple replicates of samples from
multiple individuals must be performed for confirmation.
In addition, it is possible that the balance of release
versus degradation may differ significantly according to
the biofluid type (e.g. the proteins present, proportion of
exRNAs tightly associated with protein-containing com-
plexes and concentration and types of RNases present),
and this issue is also in need of systematic study.
DNase treatment. There has been concern in the Extra-
cellular RNA Communication Consortium regarding poten-
tial contamination of exRNA preparations with cfDNAs,
which could interfere with accurate quantification of
the overall exRNA concentration using spectrophoto-
metric or fluorescent nucleic acid binding dye-based
methods. Methods that do not effectively remove DNA
can be easily remedied using a DNase treatment step.
Some investigators worry that preparations of DNase
could be contaminated with RNases (despite the avail-
ability of certified preparations of RNase-free DNase
from several manufacturers). Therefore, they use a DNase
step selectively when planning to use a downstream assay
that would be confounded by contaminating DNA.
Methods that do not include an organic extraction tend
to be more prone to significant extracellular DNA con-
tamination, as phenol/chloroform extraction perfor-
med in acidic conditions causes RNA to partition in
the aqueous phase with DNA in the organic phase. For
some downstream assays, co-purified DNA can result
in inaccurate measurements of exRNA yield. It can also
be the source of false signals, because even trace levels
of DNA may be detected by sensitive assays such as
qRT-PCR and some NGS library preparation methods.
However, it should be kept in mind that exDNA may also
have functions and merit as biomarkers.
The Laurent lab performed a preliminary study using
serum samples from 2 patients. The researchers isolated
RNA from each of the samples using the Exiqon bio-
fluids kit and treating them with either no nuclease, RNase,
DNase or both RNase and DNase. They used RiboGreen
for total RNA quantification, the RNA Pico Bioanalyzer
(Agilent) to examine nucleic acid size distribution and
qRT-PCR to quantify a specific miRNA, miR-486. It was
observed that the Bioanalyzer (Agilent) tracings for the
exRNA samples without any nuclease treatment included
several high molecular weight peaks that disappeared with
DNase digestion. qRT-PCR (using the same amount of
input RNA according to the RiboGreen assay) confirmed
that the CT values for miR-486 for the DNase-treated
samples were about 1 CT lower than for the non-treated
samples. This finding is consistent with the conclusion that
DNA contamination in the non-treated samples was
causing the RiboGreen quantification to overestimate
the RNA concentration by about 2-fold. As expected,
RNase treatment resulted in a 20-fold decrease in the
quantity of miR-486.
RNA phosphorylation. Several Extracellular RNA Com-
munication Consortium groups perform RNA phosphory-
lation of the isolated exRNAs prior to next-generation
library construction when using methods that incor-
porate adaptor sequences by RNARNA ligation. The
rationale for this manoeuver is that degraded RNAs
fragments, or RNAs that have undergone base hydrolysis,
frequently do not have the 5? phosphate necessary for
5? adaptor ligation, or they have a 3? phosphate, which
prevents 3? adaptor ligation. In this situation, 5? phos-
phorylation and 3? dephosphorylation of the input RNA
with T4 polynucleotide kinase (T4 PNK) can improve
library yields.
Several of the groups in the Consortium have noted
that exRNA isolated using the miRCURY Biofluids kit
produced low library yields of small RNA. The Das
group showed that while the yield of RNA using the
miRCURY biofluids kit was equivalent to other kits,
depending on type of library preparation method chosen,
the RNA isolated using this method required the use
of RNA phosphorylation with T4 PNK to yield usable
libraries for RNA-seq. The Laurent group reasoned that
because T4 PNK displays significant sequence bias,
it would be reasonable to use OptiKinase (Affymetrix),
a modified form of T4 PNK that does not display this
bias (62). However, OptiKinase (Affymetrix) does not
have 3? dephosphorylation activity (62), so they used a
mixture of T4 PNK and OptiKinase (Affymetrix) to treat
exRNA isolated using the miRCURY Biofluids kit prior
to library construction using the NEBNext Small RNA
Library Prep Set (New England Biolabs, Ipswich, MA,
USA). They found that the non-phosphorylated samples
yielded a significant fraction of shorter products corre-
sponding to adaptor dimers. At the same time, for the
samples treated with T4 PNK and OptiKinase (Affymetrix),
the lengths of nearly all of the products were consistent with
adaptors attached to miRNA or piRNA inserts, and the
overall yield of products of the desired size was approxi-
mately 20-fold higher. However, when the libraries made
from phosphorylated and non-phosphorylated RNA sam-
ples were sequenced, researchers found that the phosphory-
lated samples showed a shift in the distribution of reads.
They noted a markedly increased percentage of reads
mapping to rRNA sequences and concomitant decreases
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in the percentages of reads mapping to non-rRNA
transcripts, including miRNA, tRNA and piRNA
sequences. These results highlight the need to complete
the entire NGS analysis process for evaluation of the
effects of upstream experimental variables, rather than
depending on commonly used proxy measures of library
yield (such as bioanalyzer (Agilent) tracings, nucleic
acid quantification, or qPCR) for evaluation of library
quality.
Downstream evaluation of EVs and exRNAs
The downstream evaluation of EVs and exRNAs in
biofluids can be divided into 2 categories: assessment
of biological function of EVs and molecular analysis of
purified exRNAs.
Assays of biological function
Assays for evaluation of the biological function of EVs
are inherently difficult to standardize, as they depend on
the biological system and the specific function under
investigation. Major questions posed by Consortium
members in this area include the following:
a. Do EVs from cell culture supernatants have similar
function to those from the corresponding cells in
vivo? The answer to this question may vary according
to cell culture conditions. There may be a variety of
EV subpopulations, with some subpopulations that
are shared between in vitro and in vivo cells, but
others that may be released in vitro in response to
specific stimuli that are encountered in the cell culture
milieu. For example, the Breakefield group observed
that cells release more EVs when they are less con-
fluent, and live imaging has suggested a high exchange
rate of EVs among cells. This observation is impor-
tant when trying to isolate EVs from cells in vitro, as
higher numbers of cells do not necessarily correspond
to higher numbers of EVs. This correlation has been
tested on a limited number of cell types and may not
be representative of other cell types.
b. What is the impact of different experimental manip-
ulations on EV function (e.g. filtration, high-speed
centrifugation and ultracentrifugation)? This is an
area of investigation that has not been systematically
addressed.
c. Are there in vitro or in vivo functional assays that are
generally useful? Different methods have been used
to label EVs to track their fate in culture and in vivo
(63). The usual method is to employ a lipophilic
fluorescent lipid dye (e.g. PKH67 (Sigma-Aldrich) or
XenoLight DiR (PerkinElmer, Waltham, MA, USA))
that intercalates within the vesicle membrane. This
method can be a very effective way of tracking vesicle
uptake over relatively short time periods (hours).
Caveats are that the unbound dye residues can form
precipitates that register as nanoparticles, and that
the half-lives of these dyes are much longer than the
vesicles, with the dyes being able to intercalate into
other membranes in cells. Others have labelled vesicle
membranes with fluorescent membrane proteins fused
to myristoylation and/or palmitoylation peptide sig-
nals (64) or to EV membrane proteins, such as CD63
or CD81 (65,66). In vivo distribution studies of EVs
administered intravenously report different half-
lives depending on the labels used, with some dyes
showing long retention times [24 hours (67,68), a
membrane-bound luciferase label giving a 2-phase
exponential decay half-life of approximately 3060
minutes to 23 hours (69) and vesicles labelled with
biotinylated lectins having a 2-minute half-life (70)].
Molecular analysis
The repertoire of exRNA released by various cells and
detected in body fluids is as yet incompletely defined. A
number of low-, medium-, and high-throughput profiling
platforms are available for characterization of exRNAs,
including qRT-PCR, NanoString, microarrays and NGS.
The choice of methodology for a particular project should
depend on its specific goals and experimental settings,
but it should be kept in mind that different expression
profiling technologies will introduce various sources
of bias, which will hamper interstudy comparisons and
integrative analysis of the resulting datasets.
Cross-platform comparisons
Comparisons across different analysis approaches have
identified some of the important types of systematic bias.
In the most comprehensive study to date focused on
miRNA expression platforms, Mestdagh et al. compared
12 commercial platforms available from 9 major vendors
(71). This miRQC study included hybridization, qRT-PCR
and NGS-based profiling of human tissues and serum
RNA, as well as of a set of positive and negative control
samples. Assessment of several performance metrics, such
as specificity, required input, sensitivity, titration response,
accuracy and reproducibility, enabled identification of
strengths and weaknesses for each particular method. As
expected, superior sensitivity, critically important for low-
input exRNA samples, was observed for qPCR-based
platforms. Of note, the average validation rate for differ-
entially expressed miRNAs was 55% between any 2
platforms, indicating a need for validation experiments
using an alternative platform. These results suggest that
similar rigorously designed comparative studies evaluat-
ing profiling technologies for other protein-coding and
non-coding RNA species, especially in low-input condi-
tions, are critically needed.
NGS library preparation methods
It is well appreciated that using NGS for gene expression
profiling in different tissues has allowed investigators to
Louise C. Laurent et al.
12
(page number not for citation purpose)
Citation: Journal of Extracellular Vesicles 2015, 4: 26533 - http://dx.doi.org/10.3402/jev.v4.26533
examine cellular processes in health and disease in un-
precedented detail. NGS offers the possibility of discovery
of disease-specific exRNA biomarkers, including coding
RNAs, short and long non-coding RNAs and novel RNAs
that have not previously been mapped to the human
genome. At the same time, the use of NGS for exRNA
discovery involves several unique challenges. Burgos
et al. (72,73) were able to successfully profile exRNA
from plasma and CSF after optimizing exRNA isolation
using several commercially available kits. The use of the
mirVana PARIS (Life Technologies) isolation kit fol-
lowed by the Illumina TruSeq small RNA library
preparation protocol (Illumina, Inc., San Diego, CA,
USA) produced approximately 37% of reads mapping to
miRNA for plasma and 27% mapping to miRNA for
CSF, with low variability between technical replicates.
Similarly, Williams et al. (15) obtained 2 million
mappable reads/sample (no mapping rate reported)
from small RNA sequencing of exRNAs from plasma.
Tsui et al. (74) obtained 312 million analysable reads/
sample (no mapping rate reported), and Koh et al. (75)
obtained 16 million mappable reads/sample (mapping
rate of 80%) from plasma from long RNA-seq data.
Other groups have used NGS to profile small exRNAs in
exosomal and non-exosomal fractions from blood (76)
and urine (77). The Wang group has compared results from
3 small RNA sequencing library preparation protocols
(78). Although the results of these studies indicate the
feasibility of using NGS to characterize exRNAs from a
variety of biofluids, they are difficult to compare to each
other, given differences in biofluid type and methods for
RNA isolation and NGS library construction.
There is strong consensus in the Consortium that
standardized and robust methods for next-generation
library construction from exRNA samples for both small
and long RNA sequencing, and a systematic characteri-
zation of biases would be extremely valuable. There are a
number of papers comparing cDNA synthesis and NGS
library preparation kits (13,7888). From these published
reports, which include studies with bulk, low-input,
single-cell and degraded cellular RNA samples, it is ap-
parent that different methods vary greatly in ease of use,
robust library preparation for very low input samples,
handling of ribosomal RNA in the input sample (i.e.
depletion vs. avoidance) and options for acquiring strand-
specific data. Careful consideration of the results from
these published comparisons can help with selection
of library construction methods for exRNAs. However,
unique features of exRNAs (e.g. variability in the types of
RNAs present, which can differ among biofluids and
vesicle/particle types) make it difficult to extrapolate results
obtained using cellular RNA samples to exRNA samples.
Some exRNA-specific studies have been performed by
a few Extracellular RNA Communication Consortium
member labs, but large-scale, rigorous studies of yield,
variances and sequence-specific biases specifically for
NGS of exRNAs have yet to be performed.
The Das group assessed 3 different library preparation
methods [NEBNext Small RNA Library Prep Kit (New
England Biolabs), ScriptSeq RNA-Seq Library Prepara-
tion Kit (Illumina) and the SMARTer Universal Low
Input RNA Kit (Clontech)] on RNA isolated using the
miRCURY biofluids kit (Exiqon) from the same plasma
sample. These 3 different libraries gave very different
mapped reads, with the NEBNext Small RNA Library
Prep Kit (New England Biolabs) yielding the highest
number of detected miRNAs and the SMARTer Uni-
versal Low Input RNA Library Preparation Kit yielding
the highest number of detected long RNAs in terms of
genes with 0 counts. Although there was some overlap
between these different methods, there was a substantial
fraction of identified transcripts that were unique to each
method. Interestingly, the correlations in reads for the
most abundant miRNA species among different library
preparation methods appeared to be reasonable, with
most of the variances being noted for the lower abun-
dance miRNA species. These results are perhaps not
surprising, given that the NEBNext Small RNA Library
Prep Kit (New England Biolabs) is designed specifically
for sequencing of small RNAs, while the SMARTer
Universal Low Input RNA Kit and the ScriptSeq RNA-
Seq Library Preparation Kit are designed for sequencing
of long RNAs. The SMARTer kit uses a template
switching approach, which may result in higher efficiency
reverse transcription and better performance in long
RNA sequencing compared to the ScriptSeq kit.
The Wong group at UCLA used 2 commercially
available kits [the NEBNext Small RNA Library Prep
Kit (New England Biolabs) and the NEBNext Ultra
Directional RNA Library Prep Kit (New England Bio-
labs) with pretreatment with RNase R (Illumina)]. Syn-
thetic spike-in RNAs were added to the total RNA samples
purified using the TRIzol LS method from saliva samples
to serve as internal standards to evaluate library efficiency,
reproducibility, to normalize data across different samples
and to calculate absolute RNA abundance. The resulting
data were mapped to miRBase, piRNABank, RFam, the
Human Oral Microbiome Database, UCSC KnownGenes,
Gencode and Noncode. These studies have provided an
initial assessment of the exRNA landscape of human saliva;
they highlight the unusual abundance of piRNAs, as well
as the first description of circular RNA, in saliva (89).
The Van Keuren-Jensen laboratory tested 3 whole
transcriptome amplification kits (to make and amplify
double-stranded cDNA) and 3 library construction kits
(to ligate adaptors and amplify the final library). The
3 cDNA synthesis and amplification kits were (a) the
Ovation RNA-Seq System V2 (NuGEN, San Carlos, CA,
USA), (b) the Ovation RNA-Seq FFPE System (Nu-
GEN; the researchers reasoned that this kit might
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provide better coverage of exRNAs, which have a large
percentage of small and potentially fragmented RNAs)
and (c) the SMARTer Universal Low Input RNA Kit
(Clontech). The 3 library construction kits were (a) the
NEBNext Ultra DNA Library Prep Kit for Illumina
(New England Biolabs), (b) the Ovation Ultralow
Library Systems (NuGEN) and (c) the KAPA Library
Amplification Kit (Kapa Biosystems, Wilmington, MA,
USA). The starting material was 5 ng RNA isolated from
2 pooled plasma samples using the mirVana PARIS kit
(Life Technologies). For the Ovation FFPE kit, 2 pools
with 100 ng were tested to see if increasing the input
RNA changed the number of detected RNAs dramati-
cally. Each pool was tested using all 9 combinations of
cDNA synthesis/amplification and library construction
kit. For every sample, 95% of all reads could be
mapped using STAR (90), with 5294% of mapped reads
mapping uniquely. In most cases, the reads that mapped
to more than one location in the genome were quite
short. For the cDNA synthesis kits, the Ovation FFPE
and SMARTer cDNA and amplification kits performed
the best (with unique mapping rates 70% and compar-
able library complexity). All 3 of the library construction
kits appeared to give similar results. In order to decrease
the percentage of reads mapping to rRNAs, researchers
also performed additional limited testing of ribo-depletion
using the Ribo-Zero Gold kit (Illumina), with modifica-
tions recommended by Clontech for samples with low
starting amounts of RNA. However, extensive additional
testing is warranted.
The state of the field for RNA-Seq is changing rapidly,
with new methods (91,92), new kits and new versions of
existing kits becoming available all the time. The SAS
WG has formed an RNA-seq subgroup to utilize the
preliminary results from member groups to design future
systematic studies that can be performed in a controlled
manner across several labs to ensure generalizability of
results.
Systematic bias in small RNA sequencing library
preparation methods
Sequence-specific bias has been well recognized as a
problem. There have been a handful of published studies
measuring the same RNA sample using different com-
mercial protocols and comparing the resulting read
numbers for the same miRNA (7981) or using synthetic
miRNAs to systematically compare results using different
mutant ligases and ligation conditions (80,81,93). It is
now clear that that the difference between the numbers
of reads for the same miRNA between 2 protocols can
be as much as 100-fold (80). Recently, a number of issues
related to sequence-specific bias were reviewed (82), and
several suggestions were made to mitigate the bias of
measurements using RNA-seq (81,83,93).
The Galas group has begun systematically investigat-
ing the effects of sequence specificity on the read frequen-
cies of synthetic oligonucleotides using different library
construction protocols. The approach has been to use
very large sets of small synthetic ribo-oligonucleotides
(e.g. 65,000 different 23-mers) to study the effects of
sequence and protocol differences. The conclusions from
these results are in agreement with previous results in
that there is a difference of approximately 4 orders of
magnitude between the highest and the lowest of the read
frequencies resulting from libraries constructed from equi-
molar populations of ribo-oligonucleotides. The Galas
group has found that the distributions of frequencies are
quite similar between different protocols [e.g. TruSeq
Small RNA Preparation Kit (Illumina) and NEBNext
Small RNA Sequencing Library Preparation Kit
(New England Biolabs)], but that the representations of
individual ribo-oligonucleotides can vary significantly
within these distributions. Important questions that
have arisen are how much of the sequence is needed to
predict the read frequency and whether the 5? and 3?
terminal sequences act independently in determining to
overall read frequency. These preliminary results suggest
that additional systematic studies are needed in order to
both optimize the library construction protocols and to
construct procedures for computational inference of
molecular concentrations from NGS data. The research
community will need these kinds of systematic studies to
fully characterize the sources of bias, to mitigate bias in
protocols and to allow corrections to the read frequencies
in determining the best estimates of the actual specific
RNA concentrations in the original RNA sample.
Data normalization
Due to technical variations in sample processing and
exRNA extraction and analysis, proper normalization is
critical for consistent detection of true biological differ-
ences between samples. For qRT-PCR and NGS, it would
be very useful if endogenous reference RNAs were iden-
tified. Exogenous spike-in synthesized miRNAs such as
C. elegans miR-39/54/238 may be helpful, but are not
sufficient, because they lack the capacity to normalize
biological and pathological variations. For NGS, other
normalization approaches (e.g. global scaling, distribu-
tion-based normalization or RPKM) can be applied, but it
is as yet unclear what the optimal approach will be for
exRNA data. To identify endogenous controls, it will be
essential to perform a systematic survey of total exRNA
profiles by RNA sequencing in large populations with a
wide variety of health conditions. For any given test
exRNA that one would wish to interrogate, the optimal
endogenous control RNA would be of the same RNA bio-
type, highly conserved across species, similar in abundance
to the test exRNA and stably and universally expressed
regardless of technical or biological variance (94).
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For circulating miRNA quantification, miR-16-5p has
been used as internal reference control (95). However,
serum or plasma prepared from haemolysed blood speci-
mens may contain levels of miR-16-5p that are increased
by 2030 fold (96), diminishing the utility of miR-16-5p
as an endogenous control. Liang Wang from the Patel
project has performed studies aimed at identification of
novel internal controls for exRNA quantification (78,97).
In these experiments, plasma-derived exRNA transcrip-
tome profiles from 192 individuals with various health
conditions were generated; an analysis pipeline including
the Bestkeeper (98) and Normfinder (99) algorithms was
used to estimate the most stable transcripts among highly
abundant exRNAs. This analysis revealed several exRNA
candidates that were relatively stable across these indivi-
duals regardless of age, gender and health conditions. The
most notable candidates include miR-30a-5p and miR-
30e-5p for miRNA (100), PIR35469 and PIR61647 for
piRNA, and RN7SK for lncRNA. This preliminary study
suggests that it may be possible, at least in plasma, to
identify a set of exRNAs with relatively stable abundances,
which may be used as internal reference standards for
exRNA quantification.
Conclusions
In this report, we have outlined the range of methods
used by members of the Extracellular RNA Communica-
tion Consortium for biofluid collection and processing,
EV/particle enrichment, exRNA isolation and exRNA
analysis. We have attempted to show how our collective
experience has identified key variables involved in these
processes. We hope that our findings will inform future
studies aimed at developing standardized approaches that
will allow reproducible results to be obtained between
experiments and across groups. We appreciate that there
will never be a ‘‘one size fits all’’ solution, as different
methods will always have different strengths and weak-
nesses depending on the biological problem at hand.
However, we believe that the development of a robust set
of standardized methods that are well characterized and
validated for the most common biofluids and downstream
assays would be a valuable starting point for all future
studies. As a new and growing area of research, the exRNA
field is simultaneously faced with unique challenges and
unprecedented opportunities. The challenges include the
low exRNA concentrations present in most biofluids and
the variety of particles carrying exRNAs, many of which
co-purify in commonly used isolation methods and are as
yet poorly characterized. On the other hand, new methods
are being developed and refined at a rapid rate for puri-
fication of different particles based on size, density and
protein composition, as well as for RNA isolation and
analysis. The availability of increasingly cost effective
NGS-based analyses has been and will continue to lead
to rapid advancements in our knowledge. We also hope
that close collaborations and other interactions among
research groups, promoted by the Extracellular RNA
Communication Consortium and other organizations in
the field, such as the International Society for EVs and the
American Society for Exosomes and Microvesicles, will
further accelerate progress in this field.
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